Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Casdin Capital is a New York-based venture capital firm established in 2012 by Eli Casdin. The firm focuses on investing in information platforms within the life sciences and healthcare sectors, particularly those leveraging data analysis to advance molecular medicine, biotechnology, genomics, and synthetic biology. Casdin Capital invests across early-stage to late-stage companies, aiming to support transformative technologies in health care, gene editing, and diagnostic platforms.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
1 portfolio exit on record.
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Casdin Capital's most recent notable exit?
- Casdin Capital had a notable exit in January 2024 when C2i Genomics, a whole-genome cancer treatment intelligence platform, was acquired by Veracyte for $95M.
- Which sectors does Casdin Capital primarily focus on for investments?
- Casdin Capital shows a strong focus on the Health Tech & Life Sciences sector, with all its recorded portfolio companies and exits falling within this area.
- Can you name a key portfolio company for Casdin Capital?
- A key portfolio company for Casdin Capital is C2i Genomics, a whole-genome cancer treatment intelligence platform that was acquired in January 2024.
- What is Casdin Capital's typical investment range?
- Casdin Capital typically invests in the range of $12M to $100M.
- What funding stages does Casdin Capital participate in?
- Casdin Capital has participated in A Round and B Round funding stages.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2012 |
|---|